Skip Navigation Links
SEARCH  



 
Bookmark and Share
Bioheng Biotech received Orphan Drug Designation from the U.S. FDA for the treatment of T-ALL.
NANJING, China, June 20, 2021 /PRNewswire/ -- Nanjing Bioheng Biotech Co., Ltd. Announced UCAR T cell therapy product targeting CD7, code CTD401, received Orphan Drug Designation (ODD) from the U.S. Food and Drug Admin...

Full "IntellAsia: Resources" article




Disclaimer | Terms Of Use And Privacy Statement


© Metals News. All rights reserved.